Sepsis and Septic Shock is a recent study from Decision Resources, Inc., that examines how new drugs that directly target the inflammatory and coagulation abnormalities associated with sepsis will create a new paradigm in the treatment of sepsis and septic shock and drive a more than fourfold market increase by the close of our 2000-2010 study period.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION ) Vast Unmet Need and Enormous Commercial Potential
The commercial potential for manufacturers who are able to effectively market a sepsis therapeutic is vast. Sepsis is characterized by a high incident population and high unmet need, and no therapies are available to treat the inflammatory disorders and cascade events that lead to sepsis and septic shock. Furthermore, a product demonstrating even a modest reduction in the significant ICU costs associated with sepsis can command and justify a significant price premium.
The Introduction of Novel Therapies Targeting the Inflammatory and Coagulation Cascade Will Drive Rapid Market Growth
Several pharmaceutical and biotechnology companies are developing agents for the treatment of sepsis and septic shock in response to this vast market need. Experts in all of the seven major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) are enthusiastic about Eli Lilly's recombinant human activated protein C (rhAPC; Xigris) and indicate that this agent is likely to be the first market entry of an immunomodulator that directly targets the pathophysiology of septic shock. If the efficacy and safety shown in Phase III trials hold up in the wider clinical setting, and if Lilly can make it through the regulatory hurdles, Xigris could be a blockbuster.
Beyond being the first therapy to target the underlying pathophysiology of sepsis, Xigris will have wider implications for the market:
* The management of sepsis will fundamentally change as it will become increasingly important to identify early in the disease process patients who are more likely to respond to therapy. * Results from Xigris trials provide proof of concept that ameliorating homeostatic abnormalities that occur in sepsis can halt the progression of sepsis and improve survival. This therapy will open the doors for a host of additional promising therapies in development. * The availability of a drug to treat severe sepsis and septic shock will spur further research in sepsis diagnostics, prognostic markers, and basic science. * It will become increasingly important for physicians to be able to differentiate and categorize patients according to their fundamental pathophysiologic abnormalities and direct therapy accordingly.
Sepsis and Septic Shock is part of Infectious Disease, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/ .
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2525 (fax), or email@example.com. In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or firstname.lastname@example.org. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553, or